Sponsored by
This compassionate use program is for Glioblastoma (and any other cancer) patients who have mutations in the MAPK pathway including these mutations: KRAS, NRAS, HRAS, BRAF, MEK, and ERK, Take a look at your pathoilogy report and see if any of those mutations are present. If they are, ask your doctor about this program.
Disclaimer: I own stock in xCures and work as a paid consultant for them.